EUVIMEDOpdag EUVIMED
Video/Audio

A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice

Hugo Nordin, Noma Assad, Alexis Nguyen, Trecy Gonçalves, Adrien Picod, Feriel Azibani

Journal of Visualized Experiments · 2026

DOI: 10.3791/71633 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2026. Written by Hugo Nordin and 5 co-authors. Institution: INSERM UMR-S 942 MASCOT, Cardiovascular Biomarkers, Pathophysiology, and Therapeutic Strategies - CIRCUS, Paris Cité University. Major MEDLINE topics: Disease Models, Animal, Antibiotics, Antineoplastic, Anthracyclines, Doxorubicin.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The recent update from the European Society of Cardiology on preclinical models of cancer therapy-related cardiac dysfunction highlights a critical need for more representative and translational in vivo models. It pinpoints the need to develop models that employ immunocompetent, tumor-bearing animals, incorporating multiple strains and both sexes, to more accurately recapitulate the heterogeneity observed in clinical populations. Therefore, a clinically relevant model of anthracycline-induced cardiotoxicity (AIC) in breast tumor-bearing animals was built. According to mice' genetic background, either 4T1Luc-cells (200k cells) or PY8119-cells (200k cells) were injected in Balb/c-mice or C57Bl/6J-mice, respectively subcutaneously in the lower mammary gland of males and females. Tumor growth was controlled with bioluminescence and palpation. Once the tumor mass was detectable by palpation, 2 weeks post-tumor cell injection, animals received anticancer Doxorubicin treatment. Mice's tolerance to Doxorubicin was strain-dependent. Cardiac function was evaluated before the start of the protocol (baseline) and weekly after by cardiac ultrasound in ketamine-anesthetized mice. Cardiotoxicity was defined as a decrease in left ventricular fractional shortening of at least 10% from baseline, an absolute value 300 BPM. The protocol was reproducible with a 99% success of tumor development, and a >80% mice survival rate. Cardiotoxicity was observed in >90% of the treated mice with tumor and Doxorubicin.

Subjects

MeSH terms (MEDLINE)

Disease Models, AnimalAntibiotics, AntineoplasticAnthracyclinesDoxorubicinMammary Neoplasms, ExperimentalBreast NeoplasmsAnimalsFemaleMiceCardiotoxicityMice, Inbred C57BLMice, Inbred BALB CMaleCell Line, Tumor

Substances

Antibiotics, AntineoplasticAnthracyclinesDoxorubicin

Authors and institutions

  • INSERM UMR-S 942 MASCOT, Cardiovascular Biomarkers, Pathophysiology, and Therapeutic Strategies - CIRCUS, Paris Cité University.
  • Medical and Surgical Intensive Care Unit, University Hospital Avicenne, AP-HP.
  • INSERM UMR-S 942 MASCOT, Cardiovascular Biomarkers, Pathophysiology, and Therapeutic Strategies - CIRCUS, Paris Cité University; feriel.azibani@inserm.fr.

Cite

APA

Nordin, H., Assad, N., Nguyen, A., Gonçalves, T., Picod, A., & Azibani, F. (2026). A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice. Journal of Visualized Experiments. https://doi.org/10.3791/71633

Vancouver

Nordin H, Assad N, Nguyen A, Gonçalves T, Picod A, Azibani F. A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice. Journal of Visualized Experiments. 2026. doi:10.3791/71633

BibTeX
@article{Nordin2026,
  author = {Nordin, Hugo and Assad, Noma and Nguyen, Alexis and Gonçalves, Trecy and Picod, Adrien and Azibani, Feriel},
  title = {A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  doi = {10.3791/71633}
}
Start for free →